Successful Installation at Large Pharmaceutical Company Results in Follow on Order for Cryometrix T-150 Freezers

OREM, UT--(Marketwire - May 17, 2011) - Reflect Scientific, Inc. (OTCBB: RSCF), a provider of diverse products and services for the biotechnology, pharmaceutical and transportation industries, announced that a large US pharmaceutical company has budgeted for an order of Cryometrix T-150 ultra low temperature freezers, doubling their installed base.

A very successful pilot installation of the Cryometrix T-150 ULT freezer at one of the top ten US pharmaceutical companies has prompted additional orders for the freezer. The client was initially attracted to the Cryometrix T-150 because of the rapid freezing capability, high reliability and low operating costs of the freezer. The T-150 relies on a patented liquid nitrogen cooling technology that does not require a compressor or any environmentally unfriendly refrigerants. "We are anticipating a late Q3 installation of the next round of freezers at our client's facility. The success of the initial installation and follow on order is a testament to the versatility and acceptance of Reflect's ground breaking liquid nitrogen cooling technology," said Dr. Boyd Bowdish, Principal Scientist at Reflect Scientific.

About Reflect Scientific, Inc.
Reflect Scientific, Inc., based in Orem, Utah, develops and markets innovative, proprietary technologies in cryogenic cooling for the biotechnology, pharmaceutical, medical, and transportation markets. Among Reflect Scientific's products are low temperature freezers and refrigerated systems for laboratory, transportation and computer server room uses. For more information, visit www.reflectscientific.com.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.